NAT10 directly interacts with PARP1, promoting the acetylation of PARP1 transcripts, conferring resistance to platinum‐based drugs, regulating the breast cancer EMT process, and promoting doxorubicin resistance.135. This evidence concerns the gene NAT10 and breast carcinoma.